Abstract:Objective: This study aimed to explore the diagnostic role of a new dual receptor-targeted probe, integrin alpha(v)beta(3) and gastrin releasing peptide receptor (GRPR) targeted peptide Glu-c(RGDyK)-bombesin (RGD-BBN) labeled with technetium-99m ((99)mTc-RGD-BBN), using single photon emission tomography/computed tomography (SPET/CT) in the detection of breast tumor in comparison to ultrasound (US). Subjects and Methods: One hundred and twenty six female patients with suspicious breast lesions who had already been scheduled for biopsy or surgery were enrolled in this study. All patients had previously underwent breast US and Tc-99m-RGD-BBN SPET/CT. The US findings were evaluated according to the breast imaging report and the data system (BI-RADS). Technetium-99m-RGD-BBN SPET/CT images were interpreted independently by two experienced nuclear medicine physicians. A final diagnosis was made by histopathology of the specimens. A total of 130 lesions, 77 malignant and 53 benign lesions were ascertained. One hundred and twelve breast lesions, 69 malignant and 43 benign lesions were above 10mm in diameter and 18 breast lesions (8 malignant lesions and 10 benign lesions) were below 10mm. Results: The overall sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy of Tc-99m-RGD-BBN SPET/CT and US for breast lesions were 93.5% vs. 81.8% (P<0.05), 79.2% vs. 75.5% (P>0.05), 86.7% vs. 82.9% (P>0.05), 89.4% vs. 74.1% (P<0.05) and 87.7% vs. 79.2% (P>0.05). Technetium-99m-RGD-BBN SPET/CT detected all lesions >= 10mm and US only detected 57 (P<0.05). In malignant lesions < 10mm, US was superior than Tc-99m-RGD-BBN SPET/CT (75.0% vs. 37.5%, P<0.05). There swas no significant difference between the two methods no matter the size of the benign of the lesions. The overall sensitivity and specificity of Tc-99m-RGD-BBN SPET/CT and US for axillae lymph nodes were 87.5% vs. 71.9% (P<0.05) and 77.6% vs. 68.9% (P>0.05), respectively. For the metastatic lymph nodes of >= 10mm, the sensitivity of Tc-99m-RGD-BBN SPET/CT and of US was 88.5% and 72.1% respectively (P<0.05). Statistical analysis was not performed due to the small number of metastatic lesions of < 10mm. The specificity of Tc-99m-RGD-BBN SPET/CT and of US was not different, no matter the size of the axilla lymph nodes that had no metastases (P>0.05). Technetium-99m-RGD-BBN SPET/CT had higher sensitivity and NPV than US in detecting primary breast tumors and axilla lymph nodes and it also showed an advantage in distance metastatic lesions detection. On the contrary, specificity and PPV of the two methods were not different. Conclusion: Technetium-99m-RGD-BBN SPET/CT cannot totally replace US in the detection of primary breast cancer and axillary lymph nodes metastases. It can be used as an additional imaging tool of eliminating the necessity of surgical biopsy and histopathologic examination because of its high NPV.

Radiation dosimetry and bio-distribution of 99 mTc-rgd-bombesin peptide in breast cancer patients

Radiation Dosimetry And Bio-Distribution Of Tc-99m-Rgd-Bombesin Peptide In Breast Cancer Patients

An Exploratory Study on 99Mtc-Rgd-bbn Peptide Scintimammography in the Assessment of Breast Malignant Lesions Compared to 99Mtc-3P4-rgd2.

99Mtc-Glu-c(rgdyk)-bombesin SPECT Can Reduce Unnecessary Biopsy of Masses That Are BI-RADS Category 4 on Ultrasonography

18F, 64Cu, and68Ga labeled RGD-bombesin heterodimeric peptides for PET imaging of breast cancer

The Diagnostic Role of 99Mtc-Dual Receptor Targeted Probe and Targeted Peptide Bombesin (RGD-BBN) SPET/CT in the Detection of Malignant and Benign Breast Tumors and Axillary Lymph Nodes Compared to Ultrasound.

Pharmacokinetics and Radiation Dosimetry of Tc-99m-3prgd(2) in Healthy Individuals: A Pilot Study

Evaluation of 188Re-Mag2-rgd-bombesin for Potential Prostate Cancer Therapy

Comparative Biodistribution of Potential Anti-Glioblastoma Conjugates [111In]dtpa-Hegf and [111In]bz-Dtpa-hegf in Normal Mice

99Mtc-Labeled RGD-BBN Peptide for Small-Animal SPECT/CT of Lung Carcinoma.

Small-Animal PET of Tumors with 64Cu-Labeled RGD-Bombesin Heterodimer

Biometabolic Distribution of 99Mtc-3Prgd2 and Its Potential Value in Monitoring Chemotherapeutic Effects

Molecular Imaging and Preclinical Studies of Radiolabeled Long-Term RGD Peptides in U-87 MG Tumor-Bearing Mice

Preliminary clinical trasnationl study of 18F-(2S, 4R) 4-fluoroglutamine PET/CT imaging in 17 breast cancer patients

Evaluation of a technetium-99m labeled bombesin homodimer for GRPR imaging in prostate cancer

PET/CT Assessment of Estrogen Receptor positivity for Breast Cancer using [68Ga]Ga-RM2 Bombesin Receptor Antagonist: A Systematic Review and Meta-Analysis

Integrin Receptor Imaging of Breast Cancer Using 99Mtc-3Prgd2 SPECT/CT: Compared with 18F-FDG PET/CT

Preliminary Clinical Application of RGD-Containing Peptides as PET Radiotracers for Imaging Tumors

Impact Of Bifunctional Chelators On Biological Properties Of In-111-Labeled Cyclic Peptide Rgd Dimers

Studies on distribution and imaging of 131I-labelled RGD peptide in mice bearing tumors

MicroPET Imaging of Breast Cancer with a Dual-Targeted Molecular Probe 68Ga-Rgd-bbn